drugset

drugset / Trial / NCT00616629

Cardiac Electrophysiological Study

NCT00616629 ↗

Phase 2 Completed 55 enrolled AstraZeneca

RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures

Timeline

Start: 2008-01
Primary completion: 2008-06
Completion: 2008-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1305	Small molecule	—	Intravenous

Indications